NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases

Brain metastases (BM) are a common complication in cancer patients and have major impact on quality of life and prognosis. Chemotherapy plus immunotherapy has significant efficacy in patients with advanced non-small cell lung cancer (NSCLC) who have untreated brain metastases. In the CheckMate-9LA, nivolumab (NIVO) was combined with ipilimumab (IPI) and 2 cycles of chemotherapy and achieved high intracranial efficacy in patients with advanced NSCLC with previously treated BM. This combination was not previously assessed in patients with NSCLC and untreated BM.